WHO
REGULATORY UPDATE
Macleods’s Primaquine pediatric products prequalified
Published: 10/27/2026Detected: 10/27/2026
Summary preview
Adds three pediatric primaquine tablet presentations (2.5 mg, 5 mg, and 7.5 mg) from Macleods, India to the WHO Prequalified list under product codes MA214–MA216 for prevention of relapse of Plasmodium vivax and P.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
pediatrics
clinical
quality
safety
manufacturing
labeling
#WHO prequalification
#primaquine
#pediatric malaria
#relapse prevention
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- Invitation to a Webinar on managing reportable changes10/27/2026
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/27/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/27/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices10/27/2026
- VCP Updates - October 202610/27/2026